An informal survey taken by ISI Group analyst Mark Schoenebaum says that 82% of those questioned believe that the $11 billion deal between the two companies, worth $137 a share or an 89% premium on Pharmasset\’s stock, is too high a price. Two percent said they thought the price was too low and 16% said it was \”about right.\”

The survey also shows that more than half all respondents, or 51%, think the deal will destroy value while 49% said it will create value.

Schoenbaum collected a few comments via the web from investors who were mixed on the news. One said, \”Wayyyyyy too expensive. This will now put off both the growth and value investor bases.\” But another said, \”First time I see [Gilead] as a huge buy. Stock is pricing in.\”

Investors obviously rewarded Pharmasset with a huge buying bonanza, and the shares shot up 85% to $134.14 in midday trades Monday. Gilead, meanwhile, was hammered, losing more than 11% to $35.37.

Story Conversation

About The Tell

The Tell is MarketWatch’s fast and engaging look at trends and themes in the day’s markets. Drawing on our reporters, analysts and commentators around the world, as well as selecting the best of the rest online, The Tell is all about the pulse of the markets through news, insight and strategic information to help you make the best investing decisions. Got a tip? Tell us at TheTell@MarketWatch.com